Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Blood Adv
; 7(11): 2378-2387, 2023 06 13.
Article
in En
| MEDLINE
| ID: mdl-35973199
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
/
Isocitrate Dehydrogenase
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Aged
/
Humans
Language:
En
Journal:
Blood Adv
Year:
2023
Document type:
Article